Theravance Biopharma (TBPH) Research & Development: 2013-2025
Historic Research & Development for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $8.1 million.
- Theravance Biopharma's Research & Development fell 12.47% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 8.23%. This contributed to the annual value of $37.6 million for FY2024, which is 7.33% down from last year.
- Latest data reveals that Theravance Biopharma reported Research & Development of $8.1 million as of Q3 2025, which was down 22.67% from $10.5 million recorded in Q2 2025.
- Over the past 5 years, Theravance Biopharma's Research & Development peaked at $67.6 million during Q1 2021, and registered a low of $8.1 million during Q3 2025.
- In the last 3 years, Theravance Biopharma's Research & Development had a median value of $9.4 million in 2023 and averaged $9.8 million.
- In the last 5 years, Theravance Biopharma's Research & Development plummeted by 77.44% in 2022 and then climbed by 27.70% in 2025.
- Quarterly analysis of 5 years shows Theravance Biopharma's Research & Development stood at $31.2 million in 2021, then slumped by 50.85% to $15.3 million in 2022, then slumped by 45.84% to $8.3 million in 2023, then grew by 13.71% to $9.5 million in 2024, then dropped by 12.47% to $8.1 million in 2025.
- Its Research & Development stands at $8.1 million for Q3 2025, versus $10.5 million for Q2 2025 and $11.5 million for Q1 2025.